Pzena Investment Management, Inc. Announces November 30, 2016 Assets Under Management
Dec 07, 2016 21:15 pm UTC| Business
NEW YORK, Dec. 07, 2016 -- Pzena Investment Management, Inc. (NYSE:PZN) today reported its preliminary assets under management as of November 30, 2016. An attachment accompanying this release is available...
Star Gas Partners, L.P. Reports Fiscal 2016 Fourth Quarter and Full Year Results
Dec 07, 2016 21:15 pm UTC| Business
STAMFORD, Conn., Dec. 07, 2016 -- Star Gas Partners, L.P. (the "Partnership" or "Star") (NYSE:SGU), a home energy distributor and services provider, today filed its fiscal 2016 annual report on Form 10-K with the SEC...
Pinnacle Foods Inc. Declares Quarterly Dividend
Dec 07, 2016 21:15 pm UTC| Business
PARSIPPANY, N.J., Dec. 07, 2016 -- Pinnacle Foods Inc. (NYSE:PF) announced today that its Board of Directors has declared a quarterly cash dividend of $0.285 per share, payable on January 10, 2017 to all common...
Navigators Names Meryl D. Hartzband to Board of Directors
Dec 07, 2016 21:14 pm UTC| Business
STAMFORD, Conn., Dec. 07, 2016 -- The Board of Directors of The Navigators Group, Inc. (NASDAQ:NAVG) today announced the appointment of Meryl D. Hartzband as an independent director to the Company, effective...
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
Dec 07, 2016 21:07 pm UTC| Business
NEW YORK, Dec. 07, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it intends to offer and sell, subject to market and other conditions, shares of...
Ollie’s Bargain Outlet Holdings, Inc. Announces Fiscal 2016 Third Quarter Financial Results
Dec 07, 2016 21:05 pm UTC| Business
HARRISBURG, Pa., Dec. 07, 2016 -- Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) (“Ollie’s” or the “Company”) today announced financial results for the third quarter ended October 29, 2016. Third Quarter Summary:...
Dec 07, 2016 21:05 pm UTC| Business
VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was well-tolerated Program on track to report Cohort 3 data mid-2017...